Los auditores de la Oficina del Inspector General (OIG) encontraron que la gestión del riesgo de los datos financieros y programáticos es “generalmente eficaz” en Indonesia. Sin embargo, hicieron un llamado a adoptar un enfoque más adaptado a las inversiones del Fondo Mundial debido al tamaño y la diversidad de la carga de la enfermedad en un ambiente altamente descentralizado. La Secretaría del Fondo Mundial está trabajando con los socios de los países para hacer frente a estos problemas.
From 2003 to 2015, the Global Fund has signed 24 grants with Indonesia totaling USD 729 million to fight AIDS, tuberculosis (TB) and malaria. Indonesia commits significant domestic funds, including fully financing first line HIV and TB drugs, and malaria medications.
The OIG audit in Indonesia aimed to assess the risks to the impact of Global Fund grants in a large country of 255 million people with significant regional variations. The audit teams visited a representative sample of 60 program sites in five of Indonesia’s highly populated provinces. Overall financial and fiduciary risk management was found to be generally effective. Most health products follow the Global Fund’s pooled procurement mechanism, and local procurements over USD 15,000 are reviewed by a Local Fund Agent.
The OIG found program data collection and reporting processes were well designed and effective in most of the health facilities visited. However, weak forecasting and inventory controls were observed in 87% of the warehouses and 40% of the health facilities visited, leading to drug stock-outs. Also noted was limited HIV and TB collaboration (in 86% of TB facilities visited), and gaps in the follow-up of HIV patients (in 48% of HIV facilities visited). This could lead to low detection of HIV infection in TB patients and drug resistance due to interrupted treatment. The Ministry of Health is developing central mechanisms to address these weaknesses through its TB/HIV National Action Plan 2015-2019.
Significant regional differences in the HIV, TB and malaria disease burden, and related Global Fund investments were observed. With program implementation largely decentralized to provinces, there is varying quality in program, data, supply management and financial management, including the implementation of Global Fund or Principal Recipient recommendations. Although the Global Fund Secretariat has effective mechanisms to identify and assess material risks, a more structured framework is needed, including a more tailored approach towards risk and grant management.
The OIG found significant gaps in drug quantification and forecasting, distribution planning and inventory controls, mainly at the provincial sub-recipient level. Stock-outs of at least one essential drug were found in 53% of warehouses and 33% of facilities visited, exposing the programs to treatment disruption risks. Expired drugs were found in 63% of warehouses and 33% of facilities visited, leading to financial losses. The OIG found that 56% of warehouses and 69% of facilities visited did not follow good storage practices, leading to risks of damage to drugs and their effectiveness.
The issues are being addressed by the Global Fund’s Indonesia Country Team, which has worked with technical partners to align technical assistance plans, including supporting the Ministry of Health in implementing its drug management policy.